- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
FDA probe of diabetes medications hurts drugmakers' stock
March 15, 2013
Bloomberg News, Associated PressShares of several pharmaceutical companies that make diabetes medicines, including Eli Lilly, fell after U.S. regulators warned
they are looking into potential risks of drugs in two classes of diabetes treatments.
MoreDrugmakers, Interpol ramp up fight against fakes
March 12, 2013
Associated PressMore than two dozen of the world's largest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., have
agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs.
MoreOverseas tax savings for U.S. drugmakers under threat
March 11, 2013
Bloomberg NewsEli Lilly and Co. and five other big drugmakers avoided paying $7 billion in U.S. taxes last year by shifting their profits
overseas. The strategy has drawn the ire of some legislators.
MoreLilly sues Genentech to invalidate Erbitux-related patents
March 2, 2013
Bloomberg NewsEli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments
for cancer and autoimmune diseases.
MoreTestosterone for diabetes may be new market for Lilly, others
February 25, 2013
Bloomberg NewsResearchers suspect the sex hormone known to increase libido and musculature could also play a role in preventing a form of
diabetes that tends to strike later in life and afflicts more than 330 million people worldwide.
MoreLilly to expand partnership with diagnostic firm
February 14, 2013
IBJ Staff and Associated PressDiagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could
identify patients who could be helped by Lilly's drugs.
MoreLilly halts late-stage testing of rheumatoid arthritis drug
February 7, 2013
Bloomberg NewsEli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective.
The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
MoreLilly aims to submit five new drugs for approval
February 4, 2013
J.K. WallWith Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s
interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit
five new drugs for regulatory approval this year.
MoreLilly's profit drops 4 percent, but beats analysts' estimates
January 29, 2013
J.K. WallPrice increases and sales gains helped Eli Lilly and Co. offset declining revenue from its former blockbuster Zyprexa in the
fourth quarter, allowing the company to beat analysts' expectations and raise its 2013 profit forecast.
MoreEli Lilly and Co.'s rebound bolsters endowment
January 19, 2013
Dan HumanThe value of Lilly Endowment Inc.’s principal holding—Eli Lilly and Co. stock—has increased nearly $2 billion
over the past two years, bolstering the private foundation’s philanthropic firepower after a decade of declining or
stagnant assets.
MoreLilly drug chosen for Alzheimer's prevention study
January 18, 2013
Associated PressResearchers have chosen an experimental drug by Eli Lilly and Co. for a large federally funded study testing whether it's
possible to prevent Alzheimer's disease in older people at high risk of developing it.
MoreLilly's Amyvid receives European approval
January 16, 2013
Associated PressEuropean regulators approved the use of an imaging agent from Eli Lilly and Co., which can help doctors diagnose Alzheimer's
disease.
MoreLilly competitor gets backing on diabetes drug
January 10, 2013
Bloomberg NewsJohnson & Johnson, the world’s largest seller of health-care products, won the backing of U.S. advisers for a diabetes pill
the company is seeking to make the first in a new family of drugs for managing blood sugar.
MoreLilly settles with four sisters in DES cancer case
January 9, 2013
Associated PressFour sisters who claimed their breast cancer was caused by a drug their mother took during pregnancy in the 1950s reached
a settlement Wednesday with Eli Lilly and Co. in the first of scores of similar claims around the country to go to trial.
MoreDrug sold by Lilly caused cancer, women claim at Boston trial
January 8, 2013
Associated PressIn opening statements Tuesday, a lawyer for Indianapolis-based Lilly told the jury there is no evidence the synthetic estrogen
known as DES causes breast cancer in the daughters of women who took it.
MoreBig drug deals expected to return in 2013
January 7, 2013
Bloomberg NewsPharmaceutical companies including Pfizer Inc., Bristol-Myers Squibb Co. and Eli Lilly and Co. could be ready to start making
major acquisitions again.
MoreLilly's 2013 profit forecast tops expectations
January 4, 2013
Associated PressEli Lilly and Co. forecasts its 2013 earnings will grow more than Wall Street expects even though the drugmaker will lose
U.S. patent protection for two more key products in the new year.
MoreTrial set to begin over pregnancy drug sold by Lilly
January 3, 2013
Associated PressFour sisters diagnosed with breast cancer are suing Eli Lilly and Co., a former maker of DES, or diethylstilbestrol, a drug
taken by their mother in the 1950s when she was pregnant. It could be the first of scores of such trials over the drug.
MoreLilly agrees to pay $29.4M to settle SEC bribery charges
December 20, 2012
J.K. WallAccording to a statement released by the SEC, Eli Lilly paid $6.5 million—and in some cases gave jewelry and spa treatments—to
win government contracts in Brazil, China, Russia and Poland.
MoreLilly OKs $1.5B share buyback, first quarter dividend
December 18, 2012
Associated PressIndianapolis-based drugmaker Eli Lilly and Co. said Monday that its board authorized a $1.5 billion share-repurchase program,
which the company expects to complete next year.
MoreLilly finds solace in new Alzheimer's study
December 17, 2012
J.K. WallEli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published
new research that the pharmaceutical company thinks confirms it is on the right track.
MoreLilly discontinues late-stage trial in rheumatoid arthritis
December 13, 2012
Bloomberg NewsEli Lilly and Co. said it discontinued a last-stage trial of experimental rheumatoid arthritis drug tabalumab for lack of
efficacy. Lilly is still evaluating the drug in the two other late-stage studies.
MoreLilly notifies Canada about NAFTA complaint on Strattera patent
December 6, 2012
Bloomberg NewsEli Lilly and Co. notified Canada it plans to file a trade complaint, claiming court decisions invalidating one of the company’s
patents breach international obligations.
MoreLilly chief says China too slow in approving new drugs
November 28, 2012
Bloomberg NewsChina takes eight years longer on average to approve drugs than other major countries, and U.S. drugmakers are looking at
ways to help speed things up, Eli Lilly and Co. CEO John Lechleiter said.
MoreLilly donating $12.4 million to United Way
November 19, 2012
IBJ StaffEli Lilly and Co. said Monday it plans to give $12.4 million to the United Way, the largest single charitable donation in
the company’s history.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
It's also across the street from Fogo de Chao and Morton's....
Yep, the haters are trying to make good news bad. I guess it is hard to get people to believe the series is dying when they are gaining new sponsors.
David Copperfield! I remember watching his specials on TV when I was little.
Don't forget this is next to an MMA gym, a pawn shop, and some abandoned spaces.
Good project for Zionsville - A group who has owned the property for many years has waited and worked patiently to bring highest and best use development to a major corridor, and mix that in with the great downtown you have. Win Win. All the Best to Pittman Partners and Zionsville.